Celsion to Present at Three Investment Conferences in October
September 30 2021 - 9:00AM
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company
focused on DNA-based immunotherapy and next-generation vaccines,
today announced that management will present at the following
investment conferences in October:
- Chardan’s 5th Annual Genetic
Medicines Conference. Michael H. Tardugno, Celsion’s chairman,
president and chief executive officer, and Khursheed Anwer, Ph.D.,
Celsion’s chief scientific officer, will participate in a
presentation and fireside chat on October 5, 2021 at 4:30 p.m. ET.
Management will be available for 1x1 meetings on October 4 and 5,
and investors should contact their Chardan representative to
arrange a virtual meeting.
- LD Micro Main Event. Jeffrey W.
Church, chief financial officer, will present virtually at 9:00
a.m. ET on October 12, 2021.
- Alliance Global Partners’ Virtual
Healthcare Conference. Mr. Tardugno will participate in an oncology
focused panel discussion moderated by James Molloy on October 13,
2021 at 9:00 a.m. ET.
Live and archived webcasts of these
presentations will be available here.
About Celsion Corporation
Celsion is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative cancer treatments, including immunotherapies and
DNA-based therapies; and a platform for the development of nucleic
acid vaccines currently focused on SARS-CoV2. The company’s product
pipeline includes GEN-1, a DNA-based immunotherapy for the
localized treatment of ovarian cancer. ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, is under
investigator-sponsored development for several cancer indications.
Celsion also has two platform technologies for the development of
novel nucleic acid-based immunotherapies and other anti-cancer DNA
or RNA therapies. Both are novel synthetic, non-viral vectors with
demonstrated capability in nucleic acid cellular transfection. For
more information on Celsion, visit www.celsion.com.
CONTACTS:
Celsion CorporationJeffrey W.
ChurchExecutive Vice President and
CFO609-482-2455jchurch@celsion.com
LHA Investor RelationsKim
Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024